Pharma MarPHMMF -25.35%82 ROC (Joel Greenblatt) % is 2.69% as of Mar. 2026, which is 71% below its 10-year median of 9.29. GuruFocus rates PHMMF with a GF Score™ of 82/100 and a GF Value™ of $90.28 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,320 Biotechnology companies, Pharma Mar ranks better than 93.86% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Pharma Mar's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.69%.
The historical rank and industry rank for Pharma Mar's ROC (Joel Greenblatt) % or its related term are showing as below:
PHMMF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -63.02 Med: 9.29 Max: 579.9
Current: 72.54
During the past 13 years, Pharma Mar's highest ROC (Joel Greenblatt) % was 579.90%. The lowest was -63.02%. And the median was 9.29%.
PHMMF's ROC (Joel Greenblatt) % is ranked better than 93.86% of 1320
companies
in the Biotechnology industry
Industry Median: -294.23
vs PHMMF: 72.54
Pharma Mar's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
Pharma Mar (OTCPK:PHMMF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Pharma Mar ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Pharma Mar's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHMMF vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Pharma Mar's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Mar ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Mar's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Pharma Mar's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 2.69% mean?
Pharma Mar (PHMMF) has a ROC (Joel Greenblatt) % of 2.69% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Pharma Mar and its competitors. This is 71% below median its historical median of 9.29. According to the industry distribution chart, Pharma Mar ranks #81 out of 1320 companies in the Biotechnology industry, placing it in the top 6.1%.
Is Pharma Mar's ROC (Joel Greenblatt) % too high?
Pharma Mar's current ROC (Joel Greenblatt) % of 2.69% is 71% below median its 10-year median of 9.29. Based on the distribution chart, Pharma Mar ranks #81 out of 1320 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharma Mar has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Mar ranks #81 out of 1320 companies for ROC (Joel Greenblatt) %. This places Pharma Mar in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Pharma Mar and its competitors. Pharma Mar's current ROC (Joel Greenblatt) % is 2.69%, which is 71% below median its own 10-year median of 9.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (PHMMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $90.28, compared to a current price of $79.49 — trading 12% below its estimated fair value. The current ROC (Joel Greenblatt) % is 2.69%, which is 71% below median its 10-year median of 9.29. Pharma Mar's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Pharma Mar (PHMMF), the current ROC (Joel Greenblatt) % is 2.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Mar (PHMMF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued.
The current stock price of $79.49 is trading 12% below its estimated GF Value™ of $90.28.
GuruFocus considers Pharma Mar to be Modestly Undervalued.
Key valuation signals for PHMMF:
ROC (Joel Greenblatt) %: 2.69% (71% below median its 10-year median of 9.29)
GF Value™: $90.28 vs. price of $79.49 (12% below fair value)
No single metric tells the full story. See the PHMMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
82GF Score
Get the complete analysis for PHMMF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHMMF has been successfully added to your 
